Back to results
US 2020/0390913 A1Published application
Radiolabeled progastrin in cancer diagnosis
AssigneeECS-Biotracker SÀRL
InventorJean-François Floch
Life of this patent
Estimating the term…
Abstract
The present invention provides a radiotracer comprising a progastrin moiety, a chelating moiety and a radioisotope. Uses of said biomarker for imaging and detecting cancers in a subject are also provided. In one embodiment, the radiotracer is 68Ga-NODAGA-Progastrin.
Claims19
A compound, or a pharmaceutically acceptable salt thereof, comprising:
- a progastrin moiety, and
- a chelating moiety.
A method of imaging one or more cancer cells, organs, or tissues in a subject in recognized need thereof, comprising:
- a) administering a compound, or a pharmaceutically acceptable salt thereof, to said subject;
- and
- b) detecting the compound by in vivo PET or SPECT imaging,
- wherein the compound comprises:
- a progastrin moiety, and
- a chelating moiety.
3 more elements
A method of determining the localisation of a cancer in a subject in need thereof, comprising:
- a) administering a compound, or a pharmaceutically acceptable salt thereof, to said subject;
- and
- b) detecting the compound by in vivo PET or SPECT imaging:
- wherein the compound comprises:
- a progastrin moiety, and
- a chelating moiety.
3 more elements
Dependencies are inferred from the claim text.